ModerateDirect oral anticoagulants (factor Xa inhibitors)×Other opioids
Updated · Methodology
Mechanism
Apixaban inhibits clotting factor Xa, and drugs that themselves affect haemostasis add to its bleeding risk (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4, 4.5 and 5.1). The apixaban documents list serotonin and noradrenaline reuptake inhibitors (SNRIs) among these drugs (EMA, sections 4.4 and 4.5; apixaban label, US Food and Drug Administration, FDA, section 5.2). Tramadol is an opioid that, according to its US label, also weakly inhibits the reuptake of serotonin and noradrenaline (tramadol FDA label, sections 5.7 and 12.1). The documents do not address the combination with apixaban directly. The tramadol documents discuss bleeding only in connection with warfarin and other coumarins (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The documents also say nothing about either drug changing the levels of the other. Apixaban elimination involves CYP3A4 and the transporters P-gp and BCRP, and the documents do not list tramadol among their inhibitors or inducers. In vitro, apixaban did not inhibit CYP2D6 or CYP3A4, which metabolise tramadol (apixaban SmPC, EMA, sections 4.5 and 5.2).
Symptoms
The documents describe no symptoms linked to this combination. The main risk of apixaban is bleeding. Bruising, nosebleeds and haematomas are common, gastrointestinal and eye bleeding can occur, and severe bleeding can be fatal (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8; apixaban label, US Food and Drug Administration, FDA, section 5.2). The most frequent adverse effects of tramadol are nausea and dizziness. Headache, drowsiness, constipation, dry mouth, vomiting and sweating are common (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.8).
Management
The documents do not address this combination directly. According to the apixaban SmPC, apixaban is used with caution together with serotonin and noradrenaline reuptake inhibitors (SNRIs) because of the bleeding risk (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). Tramadol, according to its US label, weakly inhibits the reuptake of serotonin and noradrenaline (tramadol label, US Food and Drug Administration, FDA, section 5.7). The combination is therefore managed with the same caution. People taking apixaban are monitored closely for any sign of bleeding, and apixaban is stopped in case of severe bleeding (apixaban SmPC, EMA, section 4.4). Patients are told the signs of blood loss and asked to go to an emergency department without delay if these signs appear (apixaban FDA label, section 5.2). The documents give no reason to change the apixaban dose. Its dose restrictions apply to strong inhibitors and inducers of CYP3A4 and P-gp, and tramadol is not listed among them (apixaban SmPC, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- FDA: Eliquis (apixaban) prescribing information (2025)– FDA, DailyMed, Eliquis, E.R. Squibb & Sons, setid e9481622-7cc6-418a-acb6-c5450daae9b0, revisión 04/2025, secciones 4 y 7.1
- FDA: Tramadol hydrochloride tablets prescribing information (Amneal) (2026)– FDA label, Amneal Pharmaceuticals NY LLC, DailyMed setid 8ec4e4e5-a56e-4198-8428-6b770b9bf27d, revised 06/2026, sections 4, 5.9, 5.10, 7 and 17
- AEMPS: Ficha técnica: Tramadol, Adolonta 50 mg cápsulas (nº registro 59088), sección 4.5 (2025)– AEMPS, CIMA, nº registro 59088, revisión 11/2025, secciones 4.2, 4.4 y 4.5